Health-related quality of life as measured with the Short-Form 36 (SF-36) questionnaire in patients with recurrent vulvovaginal candidiasis by unknown
RESEARCH Open Access
Health-related quality of life as measured
with the Short-Form 36 (SF-36)
questionnaire in patients with recurrent
vulvovaginal candidiasis
Yu-Xia Zhu1†, Ting Li1,2†, Shang-Rong Fan1,3*, Xiao-Ping Liu4, Yi-Heng Liang1 and Ping Liu1
Abstract
Background: Recurrent vulvovaginal candidiasis (RVVC) has a poor therapeutic outcome and a severe impact on
women and their partners, both physically and psychologically. Health-related quality of life (HRQOL) is significantly
affected in patients with RVVC; however, little is known about HRQOL in patients with this disease. In this study,
we aim to identify the clinical and mycological characteristics of women with RVVC and the effects of RVVC on
women’s HRQOL.
Methods: We designed this study as a comparative cross-sectional study. The Short-Form Health Survey (SF-36) was
used to measure HRQOL in 102 patients with RVVC and 101 women seeking general health care (controls). RVVC
was defined as four or more episodes of proven VVC in the previous 12-month period. VVC was defined as vulvar
itching, burning, erythema, vaginal discharge, pseudohyphae or blastoconidia on a wet 10 % potassium hydroxide
(KOH)-treated vaginal slide and a positive Candida culture. Group comparisons were conducted with independent
samples t test. Correlation analysis was performed on the variables.
Results: The mean age at first diagnosis of the patients with RVVC was 30.96 years (SD 5.38), and the mean age of
the controls was 29.75 years (SD 5.83; p > 0.05). The duration of the patients’ complaints varied from 6 months to
10 years, with a mean duration of 22.28 (±21.75) months. The most common complaints were increased vaginal
discharge (102 cases, 100 %), itching (97 cases, 95.1 %), dyspareunia (65 cases, 63.7 %), burning (79 cases, 77.5 %)
and erythema (25 cases, 24.5 %). C. albicans was the predominant Candida species (86 strains, 84.3 %) in the
patients, followed by C. glabrata (12 strains, 11.8 %). C. parapsilosis (1 strain, 0.9 %), C. tropicalis (1 strain, 0.9 %),
C. krusei (1 strain, 0.9 %) and C. lusitaniae (1 strain, 0.9 %). The mean SF-36 dimension scores for physical function,
role physical, bodily pain, general health, vitality, social functioning, role emotional, and mental health were
significantly lower in the patients with RVVC than in the controls (85.20, 61.39, 77.79, 54.95, 53.17, 67.89, 52.48 and
59.17 vs. 90.20, 80.87, 87.08, 67.38, 59.69, 79.86, 68.01 and 65.38). The physical composite and mental composite
scores of the patients with RVVC were 63.06 and 64.87, respectively, which were lower than those of the controls
(75.01 and 74.87; p < 0.05).
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Conclusions: Nearly all of the patients with RVVC had clinical symptoms. In our sample, RVVC was mainly caused
by C. albicans. RVVC has negative effects on women’s HRQOL, as indicated by lower physical and mental composite
scores among the RVVC group compared with controls.
Keywords: Recurrent vulvovaginal candidiasis, Health-related quality of life, SF-36, Candida
Background
Recurrent vulvovaginal candidiasis (RVVC) defined as
four or more episodes of vulvovaginal candidiasis (VVC)
in a 12-month period and is estimated to occur in up to
5–8 % of women of child-bearing ages [1–3]. RVVC
have a poor therapy outcome and have a severe impact
on women and their partners, both physically and psy-
chologically [4–11]. The main symptoms of RVVC,
which was mainly caused by C. albicans, are itching, an
abnormal vaginal discharge and painful sexual inter-
course [6, 10, 12]. The symptoms and therapy of RVVC
seriously interfered with sexual and emotional relation-
ships of the affected women [13, 14]. Health-related
quality of life (HRQoL) is a study area that has attracted
increasing interests over the past two decades. Short-
form 36 questionnaire (SF-36), which is an instrument
for assessing quality of life, has been used in study to as-
sess the quality of life of general population and the
population with special chronic diseases world-wide
[15–25]. We use SF-36 questionnaire to investigate the




A total of 102 consecutive patients with RVVC who
attended the RTI clinic of Peking University Shenzhen
Hospital from 2014 to 2015 were invited to participate
in this study by completing data forms after their ap-
pointments. The participants who came for general
health care that is not concerned about other diseases,
which included as the following exclusions criteria, com-
prised the control group (n = 101). The inclusion criteria
of patients were: aged 18–50 years-old, generally healthy
women with RVVC. Patients were excluded from entry
if they: (1) had any other sexually transmitted disease or
gynaecological abnormality requiring treatment; (2) had
serious health problems known to effect quality of life
such as diabetes mellitus. The comparison group within
the same age range was recruited from the same clinic,
where they attended for health care, in order to repre-
sent women from a general population, not concerned
about reproductive tract infection (RTI) or other dis-
eases. RTI including bacterial vaginosis, trichomoniasis
and vulvovaginal candidiasis, were examed for all pa-
tients with RVVC and controls. The study was approved
by Peking University Shenzhen Hospital Medical Ethics
Committee and all participants provided written informed
consent prior to study.
We administered the questionnaires while the women
were waiting for their laboratory test reports. All of the
patients were seen in the clinic by one of the authors
(YXZ or TL), who made the final RVVC diagnosis
and prescribed treatment. Nearly all the patients with
RVVC and the controls completed the SF-36 ques-
tionnaire on their own at one separate room by
thinking back to their most recent VVC episodes.
Only several participants completed the questionnaire
under the help of the authors (YXZ or TL). Add-
itional information about demographic and clinical
characteristics, Candida species, and other information
pertaining to the RVVC was also collected by use of a
study form.
Case definition and Candida identification
VVC was defined as the presence of vulvar itching, vagi-
nal discharge, blastoconidia and pseudohyphae on a wet
10 % KOH-treated vaginal slide and a positive Candida
culture. The severity of each symptom such as itching,
burning, erythema, and discharge was assigned a score
on the following scale: 0 = absent; 1 =mild; 2 =moderate;
3 = severe. Patients with a severity score of 7 or greater
were designated as severe vulvovaginal candidiasis. RVVC
was defined as four or more episodes of proven infection
in the previous 12-month period. Specimens were plated
on CHROMagar (Biocell Laboratory Ltd, Zhengzhou,
China) for 24 to 48 h at 37 °C in ambient air. Strains were
identified using the standardized API Candida system (bio-
Merieux, Marcy l’Etoile, France).
SF-36 questionnaire
The SF-36 questionnaire consists of 36 items, which are
used to calculate eight subscales: physical functioning
(PF), role physical (RP), bodily pain (BP), general health
(GH), vitality (VT), social functioning (SF), role emo-
tional (RE), and mental health (MH). The first four
scores can be summed to create the physical composite
score (PCS), while the last four can be summed to create
the mental composite score (MCS). Scores for the SF-36
scales range between 0 and 100, with higher scores indi-
cating a better HRQOL [25–27].
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Statistical analysis
Statistical analysis was performed using Statistical Package
for the Social Sciences 21.0 (SPSS Inc., Chicago, IL, USA).
Descriptive statistics were used to summarize the patients’
baseline characteristics. The data are presented as number
and percentage unless otherwise indicated. Group com-
parisons were conducted with independent samples t test.
Pearson’s correlation was performed to test the correlation
among continuous variables. Spearman’s correlation was
performed to test the correlation among rank variables.
All statistical tests were two-sided (α = 0.05). P < 0.05 was
accepted as significant.
Results
The characteristics of the patients with RVVC and controls
The 102 patients with RVVC and 101 controls who ful-
filled the inclusion criteria were admitted to the study. The
mean age at first diagnosis of the patients with RVVC and
the controls was 30.96 (SD 5.38) and 29.75 (SD 5.83) years,
respectively. The duration of the patients’ complaints var-
ied from 6 months to 10 years, with a mean duration of
22.28 (SD 21.75) months. The most common complaints
were increased vaginal discharge (102 cases, 100 %), itching
(97 cases, 95.1 %), dyspareunia (65 cases, 63.7 %), burning
(79 cases, 77.5 %) and erythema (25 cases, 24.5 %). Of the
102 patients with RVVC who were recruited to participate,
one patient had a history of drug allergies, one patient had
diabetes mellitus complications, and one patient reported a
male partner with symptoms of a genital Candida infection.
No patients were infected with HIV. One hundred two
Candida strains were recovered from the vaginal swabs of
the patients with RVVC. C. albicans was the predominant
Candida species (86 strains, 84.3 %), followed by C. glab-
rata (12 strains, 11.8 %), C. parapsilosis (1 strain, 0.9 %), C.
tropicalis (1 strain, 0.9 %), C. krusei (1 strain, 0.9 %) and C.
lusitaniae (1 strain, 0.9 %).
Health-related quality of life in patients with RVVC
The mean SF-36 dimension scores for physical function,
role physical, bodily pain, general health, vitality, social
functioning, role emotional, and mental health were sig-
nificantly lower in the patients with RVVC than in the
controls (85.20, 61.39, 77.79, 54.95, 53.17, 67.89, 52.48 and
59.17 vs. 90.20, 80.87, 87.08, 67.38, 59.69, 79.86, 68.01 and
65.38), p < 0.05. The PCS and MCS of the patients with
RVVC were 63.06 and 64.87, which were lower than those
of the controls (75.01 and 74.87), p < 0.05, Table 1.
The PCS and MCS scores of the patients with RVVC
have no correlations with Candida species and VVC score,
which were based on the severity of each symptom includ-
ing itching, burning, erythema, and discharge, Tables 2
and 3. The SF 36 quality of life scale PCS and MCS score
were lower in patients with RVVC caused by C. albicans
and with high VVC score, p > 0.05.
Discussion
Characteristics of the women with RVVC
The main symptoms of yeast infections are inflam-
mation, itching, abnormal vaginal discharge and painful
sexual intercourse and urination. Such symptoms cause
Table 1 Findings of SF 36 quality of life scale in patients with
RVVC and controlsa
SF-36 scales RVVC group (n = 102) Control group (n = 101)
Mean SD Mean SD t P value
PF 85.20 16.99 90.20 12.12 2.401 0.017
RP 61.39 36.66 80.87 31.25 4.038 0.000
BP 77.79 18.33 87.08 15.01 3.946 0.000
GH 54.95 18.66 67.38 16.48 5.026 0.000
VT 53.17 14.89 59.69 14.58 3.121 0.002
SF 67.89 17.89 79.86 15.92 5.030 0.000
RE 52.48 40.37 68.01 40.10 2.730 0.007
MH 59.17 15.74 65.38 15.57 2.801 0.006
PCS 63.05 20.28 75.01 18.78 4.382 0.000
MCS 64.87 13.92 74.87 12.22 5.378 0.000
aIndependent samples t test. RVVC recurrent vulvovaginal candidiasis
Table 2 Bivariate correlations between SF 36 quality of life scale PCS and MCS with characteristics of patients with RVVC
SF 36 scale and characteristics of RVVC 1 2 3 4 5 6 7 8
1. PCS# 1
2. MCS# 0.736** 1
3. Ages of patients# 0.045 0.075 1
4. VVC score# −0.056 0.010 0.089 1
5. Itching § 0.028 0.017 0.183 0.507** 1
6. Burning § 0.087 0.086 0.134 0.510** 0.026 1
7. Erythema § −0.035 0.002 0.052 0.532** −0.013 0.192 1
8. Vaginal discharge § −0.076 0.012 −0.174 0.767** 0.090 0.218* 0.386** 1
#Pearson’s correlation was performed to test the correlation among continuous variables. § Spearman’s correlations was performed to test the correlation among
rank variables. Significance correlation at *p < 0.05 level and **p < 0.01 level (2-tailed). MCS Mental composite score, PCS Physical composite score, RVVC recurrent
vulvovaginal candidiasis
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variable but often severe discomfort and pain. Most of the
patients with RVVC have no precipitating factor. All of
our patients with RVVC had clinical symptoms. The mean
duration of RVVC in our patients was 22.28 months. C.
albicans was the predominant Candida species (86 strains,
84.3 %), followed by C. glabrata (12 strains, 11.8 %); these
findings are consistent with previous reports [6, 10, 12].
Health-related quality of life
The clinical impression is that patients with RVVC, despite
current treatment options, suffer from a substantially
impaired HRQOL, but quantifiable evidence to support
this impression is scarce. Nyirjesy et al. [14] applied sev-
eral validated pain, stress and depression measurements
to a population of physician-diagnosed patients (N = 38)
and found that 29 % had clinical depression. Aballéa et al.
[8] studied the health status and HRQOL of women with
RVVC in Europe and the USA. A total of 620 women with
RVVC were selected to complete the EQ-5D question-
naire and the SF-36 questionnaire. Of these women, 68 %
reported depression/anxiety problems during acute epi-
sodes and 54 % reported depression/anxiety when they
Table 3 Comparison of SF 36 quality of life scale PCS and MCS with VVC score and Candida species in patients RVVCa
SF-36 scales VVC score Candida species
~6 >6 C. albicans Non albicans
n 87 15 86 16
PCS, Mean (SD) 63.4254 (20.49504) 58.2576 (20.03453) 64.5119 (14.02028) 66.6544 (13.74386)
t 0.789 0.474
P value 0.432 0.639
MCS, Mean (SD) 65.1078 (13.59153) 62.3636 (17.07332) 62.4548 (21.12199) 64.5588 (15.60170)
t 0.613 0.576
P value 0.541 0.566
aIndependent Samples t test. MCS Mental composite score, PCS Physical composite score, RVVC recurrent vulvovaginal candidiasis
Table 4 Findings of SF 36 quality of life scale in patients and controls
Population PCS MCS References
Adults of the Chinese general population Normal weight 77.5 73.4 Zhu, 2015 [25]
Underweight 75.4 71.8
Overweight 78.0 73.9
Class I obese 78.4 75.1
Class II obese 76.8 75.0
Overweight older adults, Stockholm County Swedish physical activity intervention baseline 80 84 Olsson, 2015 [22]
Swedish physical activity controls baseline 83 89
Female rural-to-urban migrants, Chinese female 76.79 68.59 Wang, 2015 [24]
Patients with benign breast lumps, Chinese 75.42 68.70 Lou, 2015 [20]
Knee osteoarthritis patient, Chinese 70.37 80.94 Pang, 2015 [23]
Type 2 diabetes, Chinese 67.4 64.9 Hu, 2015 [16]
Caregiver spouses of veterans with bilateral
lower extremity amputations
Study group 70 64 Moradi, 2015 [21]
Controls: general population 73 66
Patients at Risk for CVD in Uruguay, female 64.4 64.8 Clennin, 2015 [15]
College teachers, female 71.35 65.63 Liu, 2015 [18]
Chinese psychiatrists 79.78 71.50 Liu, 2015 [19]




Patients with RVVC and controls Controls: general population 75.01 74.87 This study
RVVC 63.05 64.87
CVD cardiovascular disease, PCS Physical component summary, MCS Mental component summary
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were not experiencing episodes, compared with less than
20 % for the general population. All SF-36 domain scores
were significantly below the general population norms,
but the mental health domains were the most affected.
The results indicate that HRQOL is substantially dimin-
ished both during acute episodes and outside of these
episodes in women with RVVC.
The SF-36 is commonly used as a generic measure to
assess HRQOL. It has gained popularity as a means of
evaluating outcomes in a wide variety of patient groups
and surveys [15–25]. The findings of the SF-36 quality
of life scale in patients and controls from previous study
were shown on Table 4. Our current study results
showed that PCS and MCS of patients with RVVC were
63.05 and 64.87, which were lower than those in con-
trols (75.01 and 74.87). The PCS and MCS of control in
our study are similar to those of normal controls from a
Chinese study (PCS: 75.01 vs 77.5; MCS: 74.87 vs 73.4),
however, are lower than those of normal controls from a
Malaysia study (PCS: 75.01 vs 88.01; MCS: 74.87 vs
85.52) [17, 25]. The PCS of patients with RVVC in our
study arelower than those of patients with type 2 dia-
betes (63.05 vs 67.4). The MCS of patients with RVVC
in our study are similar to those of patients with type 2
diabetes (64.87 vs 64.9) [16]. The results of our study
were consistent with findings by Aballéa et al., who also
reported a stronger impact of RVVC on mental health
than on physical health using SF-36, albeit to a some-
what lesser extent [8]. Our data support the impression
that the subjective health status and HRQOL in women
with RVVC are significantly worse than in the general
population. An important question raised by the study
(as well as previous studies) is whether the reduction in
HRQOL among women with RVVC is attributable to
RVVC or associated comorbidities. In our current study,
the SF 36 quality of life scale PCS and MCS score were
lower (but without significantly statistical difference) in
patients with RVVC caused by C. albicans, which was
more virulence, and with high VVC score [1]. This sug-
gests the reduction in HRQOL among women with
RVVC may be attributable to the comorbidities of the
infection. The factor(s) which exactly affect the PCS and
MCS scores of the patients with RVVC are unclear and
should be further studied.
The limitations of this study were that for the SF-36
questions, we replaced “During the past 4 weeks …” with
“Thinking back to your most recent VVC…” and the sam-
ple size was determined based on only previous studies.
Conclusions
Nearly all of the patients with RVVC had clinical symp-
toms, and most had no precipitating factor. RVVC was
mainly caused by C. albicans. RVVC had negative effects
on the women’s HRQOL.
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